Media stories about Cutera (NASDAQ:CUTR) have been trending somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cutera earned a news impact score of 0.19 on Accern’s scale. Accern also gave press coverage about the medical device company an impact score of 44.5168582455394 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:

Shares of Cutera (NASDAQ CUTR) traded up 0.41% during trading on Thursday, reaching $36.90. The company’s stock had a trading volume of 90,891 shares. The company’s 50 day moving average price is $29.52 and its 200 day moving average price is $23.53. Cutera has a 12 month low of $10.54 and a 12 month high of $37.35. The firm has a market cap of $516.78 million, a PE ratio of 79.35 and a beta of 0.60.

Cutera (NASDAQ:CUTR) last announced its quarterly earnings results on Monday, August 7th. The medical device company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.10. Cutera had a net margin of 5.07% and a return on equity of 11.64%. The company had revenue of $36.40 million during the quarter, compared to the consensus estimate of $32.08 million. During the same quarter in the previous year, the company posted $0.07 earnings per share. The company’s revenue for the quarter was up 32.4% compared to the same quarter last year. On average, equities analysts predict that Cutera will post $0.52 earnings per share for the current year.

Cutera declared that its Board of Directors has initiated a stock repurchase plan on Monday, August 7th that permits the company to buyback $25.00 million in shares. This buyback authorization permits the medical device company to buy up to 6.8% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s board believes its stock is undervalued.

Several equities analysts recently issued reports on CUTR shares. BidaskClub cut Cutera from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Gabelli reiterated a “buy” rating on shares of Cutera in a report on Wednesday, August 9th. Maxim Group reiterated a “buy” rating and issued a $33.00 price target (up previously from $27.00) on shares of Cutera in a report on Thursday, July 13th. TheStreet upgraded Cutera from a “c” rating to a “b” rating in a report on Friday, August 18th. Finally, Zacks Investment Research upgraded Cutera from a “sell” rating to a “buy” rating and set a $28.00 price target on the stock in a report on Tuesday, June 20th. Six investment analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average target price of $33.25.

TRADEMARK VIOLATION WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at

In related news, Director David A. Gollnick sold 10,000 shares of the company’s stock in a transaction dated Monday, June 26th. The shares were sold at an average price of $25.08, for a total value of $250,800.00. Following the completion of the sale, the director now owns 26,641 shares of the company’s stock, valued at $668,156.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Larry Laber sold 2,563 shares of the company’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $24.36, for a total transaction of $62,434.68. Following the completion of the sale, the executive vice president now directly owns 74,203 shares of the company’s stock, valued at approximately $1,807,585.08. The disclosure for this sale can be found here. In the last three months, insiders have sold 58,597 shares of company stock valued at $1,865,451. Corporate insiders own 11.60% of the company’s stock.

Cutera Company Profile

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

Insider Buying and Selling by Quarter for Cutera (NASDAQ:CUTR)

Receive News & Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.